Emergence of macrolide-resistant *Bordetella pertussis* in France, 2024: out of China

Valérie Bouchez [1 2 3], Noémie Lefrancq[4], Julie Toubiana [1 2 3 5], Carla Rodrigues [1 2 3 *], Sylvain Brisse [1 2 3 *]

1 Institut Pasteur, Université Paris Cité, Biodiversity and Epidemiology of Bacterial Pathogens, Paris, France

2 National Reference Center for Whooping Cough and Other Bordetella Infections, Institut Pasteur, Paris, France

3 European Reference Laboratory for Diphtheria and Whooping Cough, Institut Pasteur, Paris, France

4 Eidgenössische Technische Hochschule (ETH), Zürich, Switzerland

5 Department of General Pediatrics and Pediatric Infectious Diseases, Hôpital Necker-Enfants Malades, APHP, Université Paris Cité, Paris, France

*Co-supervised the work

Correspondence: Prof Sylvain Brisse, sylvain.brisse@pasteur.fr; Unit Biodiversity and Epidemiology of Bacterial Pathogens, INSTITUT PASTEUR, 25-28 rue du Docteur Roux, 75724 Paris Cedex 15, France ; Tel : 33 (0)1 45 68 83 34

Abstract

Objectives

Pertussis is a highly contagious, potentially fatal vaccine-preventable respiratory disease, primarily caused by *Bordetella pertussis* (*Bp*). Macrolides constitute the first-line treatment for pertussis, reducing bacterial carriage and transmission. Despite consistent surveillance, only one resistant isolate had ever been reported in France before 2024 (in 2011). Here, we report 14 macrolide-resistant *Bp* (MRBP) cases, collected in France between February and November 2024, during the largest whooping cough outbreak of the last 20 years. We aimed to investigate whether these MRBP arose from macrolide-susceptible *Bp* (MSBP) in France or were instead imported.

Methods

Illumina sequencing was performed for all French isolates from 2024 and in addition, long-read sequencing was performed for the MRBP isolates. We compared the 14 MRBP genomic sequences with 1,571 macrolide-susceptible cultivated *B. pertussis* isolates collected in France (1993-2024, including 331 from 2024), the MRBP isolate from 2011, and 824 *Bp* collected in China (2018-2024), including 596 MRBP (75.2%).

Results

Phylogenetic analysis based on whole-genome single nucleotide polymorphisms revealed that the French MRBP belong to three separate branches nested within the diversity of MRBP isolates from China, suggesting three independent introductions into France. Two of these branches comprised more than one isolate, detected across several French administrative regions, indicating forward transmission and spatial dissemination. The MRBP isolates from France and China belonged to a single clade of the *ptxP*3 lineage corresponding to the previous genotype denomination MT28.

Conclusion

The rise of MRBP in France is driven by importation followed by local dissemination. This exceptional emergence is concerning, given the high expected fitness of PRN-negative *ptxP3* MRBP isolates in acellular vaccination countries. Besides vaccination, effective control of MRBP will require enhanced surveillance, strict adherence to transmission control guidelines, and prudent use of macrolides to avoid selective pressure favouring MRBP.

Keywords *Bordetella pertussis*, macrolide resistance, emergence, spatial dissemination

Introduction

Pertussis is a highly contagious vaccine-preventable respiratory disease, primarily caused by *Bordetella pertussis* (*Bp*), that can be lethal in young infants. In 2024, an intense resurgence of pertussis occurred in Europe and elsewhere (1), after circulating at very low levels since 2020. In France, an increase in the incidence of pertussis was reported (1,2).

Macrolides constitute the first-line treatment for pertussis, reducing bacterial carriage and transmission. Of major public health concern, macrolide-resistant *Bp* (MRBP) isolates have been reported in China since 2011, now reaching > 90% in some settings (4–7) . Elsewhere, only sporadic MRBP cases have been reported up to now, including one case in France in 2011 (8). In China, MRBP isolates belong to two main phylogenetic clades called *ptxP1* and *ptxP3*, which are marked by a mutation in the promoter of the pertussis toxin (*ptx*P) gene cluster (4,6). Whereas *ptxP1* MRBP isolates emerged around 2010 in China, *ptxP3* MRBP emerged around 2016 and became predominant in some areas, such as Shanghai (6,9,10). This shift in *ptxP* genotype prevalence that was observed since 2019 in China might be associated with changes in pertussis vaccines in the country, which occurred approximately since 1995 from whole cell vaccines (wP) to acellular vaccines (aP) (11). *ptxP3* isolates, particularly those that have lost the expression of the vaccine antigen pertactin (PRN), were previously inferred to have a much higher fitness, and thus to spread more rapidly, in aP-using countries (12).

Here, we report 14 MRBP isolates from France collected between February and November 2024. Through genome-wide phylogenetic comparisons, we investigated whether the MRBPs arose from macrolide-susceptible *Bp* (MSBP) in France or were imported from abroad. We discuss possible reasons for their successful dissemination in France in light of their genomic features.

Methods

Bp isolates were collected through the Reseau Microbiologique de la Coqueluche (REMICOQ) network, which comprises laboratories from the Reseau National de la Coqueluche (RENACOQ) paediatric hospital-based surveillance network and additional collaborative hospital and outpatient laboratories (1). Culture was attempted at the French National Reference Center for Whooping Cough (NRC). Microbiological identification and characterisation were performed as previously described (1,13). Antibiotic susceptibility testing was performed by disk diffusion for ampicillin, cephalexin, streptomycin, trimethoprim-sulfamethoxazole, erythromycin, azithromycin, clarithromycin and spiramycin as previously described (1) and macrolide resistance was confirmed by E-test. In cases where macrolide resistance was confirmed, an extended panel of antibiotics was tested by disk diffusion, including piperacillin-tazobactam, ceftazidime, ceftriaxone, imipenem, doxycycline, amikacin, tobramycin, and tetracycline. We sequenced all *Bp* isolates from France in 2024 (see Supplementary appendix) and compared the genomic sequences of the 14 MRBP isolates with (i) 1,572 *Bp* collected in France (1993-2024, including the MRBP isolate from 2011 and 331 MSBP isolates sequenced in 2024), and (ii) 824 *Bp* collected in China in two large studies with publicly available genomic data (2018-2024; NCBI BioProjects PRJNA908268 and PRJNA1071282), including 596 MRBP (75.2%) (4,6). Phylogenetic analysis was performed using whole-genome single nucleotide polymorphisms (SNP) as previously described (12). Briefly, the SNP-based alignment was used to reconstruct the phylogenetic relationships of the isolates, using IQ-tree v2.3.6 and a GTR+F substitution model. The figures were generated using ggtree v3.2. Additionally, Nanopore sequencing was performed on the 14 French MRBP to define the number of mutated copies of the *23S rRNA* gene (see Supplementary appendix).

Finally, in response to the emergence of MRBP in France, we adapted a qPCR assay (14) to detect MRBP directly from respiratory samples (see Supplementary Appendix, protocol posted on protocols.io (14)). Using this method, we screened the 534 pertussis-toxin positive samples (as defined by a positive qPCR for pertussis toxin gene *ptxA*) collected in 2024.

Results

Out of 345 *Bp* isolates collected across France in 2024, 14 MRBP were identified. These were collected from 4 infants under 12 months of age, 5 children aged 1 to 6 years, and 5 adults ranging from 18 to 79 years old. Of the 9 documented cases, 2 required hospitalisation, including one newborn admitted to intensive care. The 14 isolates produced pertussis toxin (PT), filamentous haemagglutinin (FHA) and the fimbriae of serotype FIM2. Whereas one isolate was PRN-positive (see branch I3, Figure 1B), the 13 others were PRN-negative (branches I1 and I2). This contrasted with the macrolide-susceptible *Bp* (MSBP) isolates collected over the study period, which all produced PRN except one. The 14 MRBP isolates carried the A2047G mutation in the 3 copies of the *23S rRNA* gene, consistent with their antimicrobial resistance phenotype. Based on antigen genes (15), the 14 MRBP isolates belonged to the same genotype, Bp-agST4, and were characterised by a *ptxP3* promoter. Differently, among MSBP isolates from 2024, 18 were characterised by a *ptxP1* promoter and 11 or these displayed a new allele for *fim3* (*fim3-26*, characterised by a synonymous mutation C87T, also observed in *fim3*-4, and an additional non-synonymous mutation leading to amino-acid substitution V165D).

Phylogenetic analysis based on whole-genome single nucleotide polymorphisms (Figure 1) revealed that the 14 MRBP belong, together with isolates from China, to a cluster of 349 MRBP isolates (Figure 1B; the *ptxP3*-MRBP clade). However, they fall into three separate branches nested within the diversity of isolates from China, indicating three independent introductions of MRBP into France. Two of these branches comprised more than one isolate (branches I2 and I1, with 11 and 2 isolates, respectively; table S2), detected across several French administrative regions, suggesting forward transmission and spatial dissemination (Figure 1C).

Eight mutations were found in isolates of the *ptxP3*-MRBP clade and may have occurred in a common ancestor preceding this lineage's expansion (see black star in Figure 1; Table 1). The first corresponds to the A2047G mutation within the *23S rRNA* gene. Two others are observed within the *prn* gene (C531T, leading to allele 150) and within a putative toxin gene (T198M in gene BP1251). Two other non-synonymous SNPs are located in genes involved in regulatory functions: V67L in BP0983 coding for a transcriptional regulator controlling *mexAB-oprM* operon (16) and A165V in BP1924 coding for

a TetR/AcrR transcriptional regulator. A further non-synonymous mutation (leading to L213P) is located in gene BP2754 coding for a penicillin-binding protein. The two remaining mutations were localised in hypothetical or miscellaneous proteins.

Regarding the screening of respiratory samples using the in-house qPCR protocol (17), out of 248 eligible samples based on *ptxA* qPCR Ct value, 3 (1.2%) were classified as MRBP. Culture attempts for these 3 samples were unsuccessful. Overall, combining isolates and respiratory samples, MRBP accounted for 2.8% (17/593) of the French 2024 tests.

Discussion

After four years (2020-2023) with low-level circulation of *Bp*, a large epidemic of whooping cough occurred in 2024 in France and other countries (1). Whereas a resurgence was expected, the emergence of MRBP was not. Only one MRBP isolate had been previously reported in France, in 2011 (18). Differently, in China, the first MRBP isolates were reported in 2011 in Shandong province, and increased in frequency in subsequent years, reaching more than 90% in some areas such as Shanghai (3,6,9,10).

Whereas the first MRBP reported from China were characterised by a *ptxP1* and *fhaB3* genotype, those identified since 2016 are mostly of the *ptxP3* and *fhaB1* genotype (4,5,7,10), and before 2024 the expansion of this particularly fast-emerging MRBP genotype was documented exclusively in China. In France, most circulating MSBP isolates since the introduction of vaccination are *ptxP3* and *fhaB1* (1,12,13,19). The only MRBP isolate from France collected before 2024 (in 2011) was of genotype *ptxP21* and *fhaB1*. The emergence of *ptxP3* and *fhaB1* MRBP isolates in France in 2024 thus raised the question of their origin: have they been introduced in the country from China or elsewhere, or are they due to a local evolution from MSBP isolates in France?

While our data suggest three direct introductions from China to France, cryptic transmission through intermediary unsampled countries cannot be excluded. More globally representative sampling and genomic analyses are needed to shed light on *Bp* global spread. Understanding the impact of global mobility versus local transmission on the emergence of MRBP is crucial for defining effective

strategies to control macrolide-resistant pertussis. Although they emerged 15 years ago in China, MRBP are only emerging in France in 2024, despite disease activity in 2010-2019 (1). As MRBP initially emerged in China within the *ptxP1* branch, we propose that this surprising 15-year delay might be due to the lower fitness of *ptxP1* isolates in acellular vaccination countries, compared to *ptxP3* isolates. The *ptxP3*-MRBP clade emerged in China only around 2016 and became predominant after 2020 (4,6). Besides, the loss of PRN expression provides a further fitness gain, particularly in the *fim3*-2 subbranch of *ptxP3* (12). The dissemination in France of the *ptxP*3, *fim3*-2, PRN-negative MRBP genotype is consistent with its high predicted fitness. Such MRBP may therefore quickly emerge in other countries too. A first PRN-negative *ptxP3*-MRBP was also reported in Finland in 2024 (20). The use of macrolides, and how it differs between countries, might be a factor favouring the transmission of this 23S rRNA A2047G-carrying genotype, relative to MSBP. Whether some of the 7 other mutations shared by these emerging MRBP isolates also contribute to an increased fitness remains to be defined.

The rise of MRBP in France in 2024 is exceptional and concerning. Effective control of macrolide resistance will require novel diagnostics, enhanced surveillance and strict adherence to transmission control guidelines. Macrolides are the drug of choice for treating other respiratory pathogens including *Mycoplasma pneumoniae,* and macrolide resistance is also reported for this species (21). To slow the rise of MRBP, prudent use of macrolides to treat pertussis and other infections or to limit their spread should be recommended to avoid selective pressure favouring resistant isolates. Besides, defining effective alternative treatments, particularly for newborns, is essential for the clinical management of future macrolide-resistant cases.

Acknowledgements

We thank the Institut Pasteur's Mutualized Platform for Microbiology (P2M) for genomic sequencing. We acknowledge support to the French whooping cough surveillance from colleagues of the REMICOQ network and Public Health France (Santé Publique France). Nathalie Armatys, Annie Landier and Julien Cordani are acknowledged for conducting the microbiological screening and characterization. Nora Zidane performed the ONT sequencing of MRBP strains.

Author contributions

CR and SB supervised the collection of isolates and data, with input from JT. VB and NL performed the genomic analyses, with input from CR and SB. VB, CR and SB wrote the manuscript, which was approved by all authors.

Transparency declaration

The authors declare that they have no conflicts of interest.

Funding

The National Reference Center for Whooping Cough and Other Bordetella Infections receives support from Institut Pasteur and Public Health France (Santé publique France, Saint Maurice, France). No specific funding was received for this study, as it was performed within the frame of the French national surveillance of whooping cough. The funders had no role in the writing or decision to submit the manuscript for publication.

References

1. Rodrigues C, Bouchez V, Soares A, Trombert-Paolantoni S, Aït El Belghiti F, Cohen JF, et al. Resurgence of Bordetella pertussis, including one macrolide-resistant isolate, France, 2024. Euro Surveill. 2024 Aug;29(31).
2. Monchausse T, Launay T, Rossignol L, Ait El Belghiti F, Brisse S, Guiso N, et al. Clinical characteristics of cases during the 2024 pertussis epidemic in France, January 2024 to December 2024. Vaccine. 2025 Apr 2;51:126862.
3. Ivaska L, Barkoff AM, Mertsola J, He Q. Macrolide Resistance in Bordetella pertussis: Current Situation and Future Challenges. Antibiotics (Basel). 2022 Nov 7;11(11).
4. Cai J, Chen M, Liu Q, Luo J, Yuan L, Chen Y, et al. Domination of an emerging erythromycin-resistant ptxP3 Bordetella pertussis clone in Shanghai, China. Int J Antimicrob Agents. 2023 Jul;62(1):106835.
5. Fu P, Zhou J, Yang C, Nijiati Y, Zhou L, Yan G, et al. Molecular Evolution and Increasing Macrolide Resistance of Bordetella pertussis, Shanghai, China, 2016-2022. Emerg Infect Dis. 2023 Jan;30(1):29–38.
6. Fu P, Yan G, Li Y, Xie L, Ke Y, Qiu S, et al. Pertussis upsurge, age shift and vaccine escape post-COVID-19 caused by ptxP3 macrolide-resistant Bordetella pertussis MT28 clone in China. Clin Microbiol Infect. 2024 Nov;30(11):1439–46.
7. Hu Y, Zhou L, Du Q, Shi W, Meng Q, Yuan L, et al. Sharp rise in high-virulence Bordetella pertussis with macrolides resistance in Northern China. Emerg Microbes Infect. 2025 Dec;14(1):2475841.

8. Guillot S, Descours G, Gillet Y, Etienne J, Floret D, Guiso N. Macrolide-resistant Bordetella pertussis infection in newborn girl, France. Emerg Infect Dis. 2012 Jun;18(6):966–8.
9. Fu P, Wang C, Tian H, Kang Z, Zeng M. Bordetella pertussis Infection in Infants and Young Children in Shanghai, China, 2016-2017: Clinical Features, Genotype Variations of Antigenic Genes and Macrolides Resistance. Pediatr Infect Dis J. 2019 Apr;38(4):370–6.
10. Fu P, Zhou J, Meng J, Liu Z, Nijiati Y, He L, et al. Emergence and spread of MT28 ptxP3 allele macrolide-resistant Bordetella pertussis from 2021 to 2022 in China. Int J Infect Dis. 2023 Mar;128:205–11.
11. Wang L, Lei D, Zhang S. Acellular pertussis vaccines in China. Vaccine. 2012 Nov 26;30(50):7174–8.
12. Lefrancq N, Bouchez V, Fernandes N, Barkoff AM, Bosch T, Dalby T, et al. Global spatial dynamics and vaccine-induced fitness changes of Bordetella pertussis. Sci Transl Med. 2022 Apr 27;14(642):eabn3253.
13. Bouchez V, Guillot S, Landier A, Armatys N, Matczak S, Toubiana J, et al. Evolution of Bordetella pertussis over a 23-year period in France, 1996 to 2018. Euro Surveill. 2021 Sep;26(37).
14. Kamachi K, Duong HT, Dang AD, Hai T, Do D, Koide K, et al. Macrolide-Resistant Bordetella pertussis, Vietnam, 2016-2017. Emerg Infect Dis. 2020 Oct;26(10):2511–3.
15. Bridel S, Bouchez V, Brancotte B, Hauck S, Armatys N, Landier A, et al. A comprehensive resource for Bordetella genomic epidemiology and biodiversity studies. Nat Commun. 2022 Jul 1;13(1):3807.
16. Fong W, Timms V, Sim E, Pey K, Nguyen T, Sintchenko V. Genomic and transcriptomic variation in Bordetella spp. following induction of erythromycin resistance. J Antimicrob Chemother. 2022 Oct 28;77(11):3016–25.
17. Valérie Bouchez, Sylvain Brisse, Carla Rodrigues. Real-time PCR amplification and genotyping of the 23s rRNA from Bordetella pertussis using the LightCycler 480. https://dx.doi.org/1017504/protocols.io.kqdg3q4y1v25/v1 [Internet]. 2024; Available from: https://www.protocols.io/view/real-time-pcr-amplification-and-genotyping-of-the-kqdg3q4y1v25/v1
18. Guillot S, Descours G, Gillet Y, Etienne J, Floret D, Guiso N. Macrolide-resistant Bordetella pertussis infection in newborn girl, France. Emerg Infect Dis. 2012 Jun;18(6):966–8.
19. Bart MJ, Harris SR, Advani A, Arakawa Y, Bottero D, Bouchez V, et al. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio. 2014 Apr 22;5(2):e01074.
20. Miettinen M, Barkoff AM, Nyqvist A, Savolainen-Kopra C, Antikainen J, Mertsola J, et al. Macrolide-resistant Bordetella pertussis strain identified during an ongoing epidemic, Finland, January to October 2024. Euro Surveill. 2024 Dec;29(49).
21. Xie P, Zhang Y, Qin Y, Fang Y, Yang N, Bai Y, et al. Macrolide resistance in Mycoplasma pneumoniae in adult patients. Front Cell Infect Microbiol. 2025;15:1496521.

Figure 1. Phylogenetic diversity and geographic dissemination of macrolide-resistant Bordetella pertussis, France 2024.

The tree was constructed based on whole genome SNPs using method described in Lefrancq *et al*. **Panel A** presents the tree obtained from the whole dataset: tree leaves are red for MRBP, (allele 13, *i.e.*, 23S rRNA A2047G mutation) or green for MSBP (allele 1); 2 isolates with a single mutated copy of the *23S rRNA* gene are colored in orange. Landmark mutation *ptxP3* is indicated at corresponding node with a black triangle. The columns indicate the country of origin (France: dark blue; China: light blue); years of collection (from 1975 to 2024), *ptxP* and *fim3* alleles (light purple for allele 1, darker purple for alleles *fim3*-2 and *ptxP3*, light grey for other or undefined alleles). The scales indicate the number of SNPs per genome. **Panel B** focuses on the emerging *ptxP3*-MRBP clade (349 isolates). Evolved SNPs shared by this clade at the black star location are detailed in the Supplementary Appendix, Table S2; the 23S rRNA mutation is indicated by a red star; a pertactin-inactivating mutation by a lightning symbol. The pertactin-negative subclade was introduced twice into France. The three introductions of MRBP into France are labelled as I1, I2 and I3 and highlighted by light grey horizontal bars (see Table S3 for details). **Panel C** presents the detailed trees of the three introductions of MRBP into France, and their geographic origins, as indicated in the map colored according to French administrative regions: orange for 'Grand Est' (GES), purple for 'Ile de France' (IDF), green for 'Auvergne Rhône Alpes' (ARA) and salmon for 'Nouvelle Aquitaine' (NAQ). Circles at branch tips are colored according to country (light blue: China; darker blue: France).
The tree can be interactively visualized in Microreact (**https://microreact.org/project/5mvNLVqAoPoT2V6y2kUPFw-bp-cnr-china-all**).

Table 1. Specific non-synonymous mutations observed in the *ptxP3*-MRBP clade

SNP position	Gene-name	Gene-id	Gene-category	SNP	Localization	Product	Nb isolates
490040	BP_RS02415	BP0478	Miscellaneous	G81A	cytoplasmic	HAD family hydrolase	346
1021456	BP_RS04885	BP0983	Regulation	V67L	cytoplasmic	LysR family transcriptional regulator	349
1317235	BP_RS06250	BP1251	Virulence	T198M	unknown	Putative toxin	349
2026485	BP_RS09590	BP1924	Regulation	A165V	cytoplasmic	TetR.AcrR transcriptional regulator	349
2641711	BP_RS12490	BP2494	Hypothetical	D165N	cytoplasmic	VMA domain-containing protein	349
2928270	pbpC	BP2754	Cell surface	L213P	cytoplasmic	Penicillin-binding protein 1C	349
1098621	prn	BP1054	Virulence	C531T	membrane	autotranporter	264
2153195	23S-rRNA	Bpr02/Bpr05/Bpr08	Ribosomal	A2047G	ribosomal	ribosomal RNA	267

SNP, single nucleotide polymorphism


A
20 subs.
Country
Year
ptxP
fim3
ptxP3
B
ptxP3-MRBP
3 subs.
Country
ptxP
fim3
I1
I2
I3
23S
1
1 and 13
13
Country
China
France
Year
<1975
2010
2024
ptxP
1
3
Others
fim3
1
2
Others
C
Introductions
Regions
I2
Regions
GES
IDF
ARA
NAQ
Regions
I3
1 sub.
Regions
I1